Medscape InDiscussion: Psoriatic Arthritis Medscape

Tune in to hear Drs Stanley Cohen and Alexis Ogdie dive into new research on switching vs cycling medications in caring for patients with psoriatic arthritis, tight control in axSpA, and more.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984265). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals.
Resources
1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients With PsA: Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry https://www.eventscribe.net/2022/ACRConvergence/index.asp?presTarget=2189995
Cycling or Swap Biologics and Small Molecules in Psoriatic Arthritis: Observations From a Real-life Single Center Cohort https://pubmed.ncbi.nlm.nih.gov/33879661/
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/35428720/
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial https://pubmed.ncbi.nlm.nih.gov/30747501/
EULAR 2023. European Congress of Rheumatology https://congress.eular.org/
GRAPPA Treatment Recommendations: 2021 Update https://pubmed.ncbi.nlm.nih.gov/35293339/
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/30499246/
Effect of a Treatment Strategy of Tight Control for Rheumatoid Arthritis (the TICORA Study): A Single-blind Randomised Controlled Trial https://pubmed.ncbi.nlm.nih.gov/15262104/
Aiming at Low Disease Activity in Rheumatoid Arthritis With Initial Combination Therapy or Initial Monotherapy Strategies: The BeSt Study https://pubmed.ncbi.nlm.nih.gov/17083767/
Long-term Follow-up of Patients in the TIght COntrol of Inflammation in Early Psoriatic Arthritis (TICOPA) Trial https://pubmed.ncbi.nlm.nih.gov/31504996/
Efficacy of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: Results of the Open-label, Pragmatic, Cluster-randomised TICOSPA Trial https://pubmed.ncbi.nlm.nih.gov/33958325/
ASAS Health Index: The "All in One" for Spondyloarthritis Evaluation? https://pubmed.ncbi.nlm.nih.gov/33004479/
Central Sensitization Has Major Impact on Quality of Life in Patients With Axial Spondyloarthritis https://pubmed.ncbi.nlm.nih.gov/35033996/
ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update https://pubmed.ncbi.nlm.nih.gov/36270658/
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists: A Retrospective Study in Three Health Systems https://acrabstracts.org/abstract/treatment-of-ankylosing-spondylitis-by-primary-care-physicians-and-rheumatologists-a-retrospective-study-in-three-health-systems/
Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Population-Based Study https://acrabstracts.org/abstract/multimorbidity-in-psoriasis-as-a-risk-factor-for-psoriatic-arthritis-a-population-based-study/
Comorbidities, Pain and Fatigue in Psoriatic Arthritis, Psoriasis and Healthy Controls: A Clinical Cohort Study https://pubmed.ncbi.nlm.nih.gov/33325531/

Experts Stanley Cohen and Arthur Kavanaugh give busy clinicians a rundown of what's new and noteworthy in the 2021 GRAPPA guidelines update.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984267). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals.
Resources
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated Treatment Recommendations for Psoriatic Arthritis 2021 https://pubmed.ncbi.nlm.nih.gov/35761070/
Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression https://pubmed.ncbi.nlm.nih.gov/15248226/
GRADE: An Emerging Consensus on Rating Quality of Evidence and Strength of Recommendations https://pubmed.ncbi.nlm.nih.gov/18436948/
US Welcomes First Adalimumab Biosimilar, Amjevita https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Impact of Clinical Domains Other Than Arthritis on Composite Outcomes in Psoriatic Arthritis: Comparison of Treatment Effects in the SEAM-PsA Trial https://pubmed.ncbi.nlm.nih.gov/35863864/

Drs Stanley Cohen and Christopher Ritchlin discuss advances in basic research for psoriatic arthritis, including new research using a humanized mouse model, combination therapy trials, and more.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984269). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview
Transcriptional Signature Associated With Early Rheumatoid Arthritis and Healthy Individuals at High Risk to Develop the Disease https://pubmed.ncbi.nlm.nih.gov/29584756/
DC-STAMP: A Key Regulator in Osteoclast Differentiation https://pubmed.ncbi.nlm.nih.gov/27018136/
Psoriatic Dactylitis: Current Perspectives and New Insights in Ultrasonography and Magnetic Resonance Imaging https://pubmed.ncbi.nlm.nih.gov/34204773/
Transcriptome Fact Sheet https://www.genome.gov/about-genomics/fact-sheets/Transcriptome-Fact-Sheet
Tumor Necrosis Factor Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK482425/
Inverse Psoriasis https://www.psoriasis.org/inverse-psoriasis/
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk https://acrabstracts.org/abstract/prediction-of-psoriatic-arthritis-tool-presto-development-and-performance-of-a-new-scoring-system-for-psoriatic-arthritis-risk/
Efficacy of Guselkumab, a Selective IL-23 Inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk Cohort (PAMPA): Protocol of a Randomised, Double-Blind, Placebo Controlled Multicentre Trial https://pubmed.ncbi.nlm.nih.gov/36564123/
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review https://pubmed.ncbi.nlm.nih.gov/33301128/
Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00034-6/fulltext
Prevention of Psoriatic Arthritis: The Next Frontier https://www.thelancet.com/pdfs/journals/lanrhe/PIIS2665-9913(23)00055-3.pdf
Ultrasound Power Doppler and Gray Scale Joint Inflammation: What They Reveal in Rheumatoid Arthritis https://pubmed.ncbi.nlm.nih.gov/31304659/
Consensus Terminology for Preclinical Phases of Psoriatic Arthritis for Use in Research Studies: Results From a Delphi Consensus Study https://pubmed.ncbi.nlm.nih.gov/33589818/
Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift https://pubmed.ncbi.nlm.nih.gov/32602263/
Abatacept Reverses Subclinical Arthritis in Patients With High-Risk to Develop Rheumatoid Arthritis -- Results From the Randomized, Placebo-Controlled ARIAA Study in RA-at risk Patients https://acrabstracts.org/abstract/abatacept-reverses-subclinical-arthritis-in-patients-with-high-risk-to-develop-rheumatoid-arthritis-results-from-the-randomized-placebo-controlled-ariaa-study-in-ra-at-risk-patients/
Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/
Arthritis Mutilans https://pubmed.ncbi.nlm.nih.gov/23430715/
Usage of C-Reactive Protein Testing in the Diagnosis and Monitoring of Psoriatic Arthritis (PsA): Results From a Real-World Survey in the USA and Europe https://pubmed.ncbi.nlm.nih.gov/35032324/
Disease Modifying Anti-Rheumatic Drugs (DMARD) https://pubmed.ncbi.nlm.nih.gov/29939640/
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis https://pubmed.ncbi.nlm.nih.gov/30499418/

Drs Stanley Cohen and Philip Mease review the 2022 ACR meeting topics, including new treatments, trial data, and what they think are the most pressing unmet needs in the field.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984271). The topics and discussions are planned, produced, and reviewed independently of the advertisers. This podcast is intended only for US healthcare professionals.
Resources
Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10972371/
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis https://www.grappanetwork.org/
American College of Rheumatology (ACR) Convergence https://www.rheumatology.org/Annual-Meeting
Bimekizumab Treatment in Biologic DMARD-Naïve Patients With Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results From a Phase 3, Randomized, Placebo-Controlled, Active Reference Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-biologic-dmard-naive-patients-with-active-psoriatic-arthritis-52-week-efficacy-and-safety-results-from-a-phase-3-randomized-placebo-controlled-active-reference-study/
Bimekizumab Treatment in Patients With Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study https://acrabstracts.org/abstract/bimekizumab-treatment-in-patients-with-active-psoriatic-arthritis-and-inadequate-response-to-tumor-necrosis-factor-inhibitors-16-week-efficacy-and-safety-from-a-phase-3-randomized-double-blind-pla/
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients With Active PsA: Pooled 16-Week Results From Phase 3 Randomized, Placebo-Controlled Studies https://acrabstracts.org/abstract/bimekizumab-improvements-in-efficacy-on-disease-activity-assessed-via-composite-endpoints-in-biologic-dmard-naive-and-tnfi-ir-patients-with-active-psa-pooled-16-week-results-from-phase-3-randomized/
Bimekizumab Versus Adalimumab in Plaque Psoriasis https://pubmed.ncbi.nlm.nih.gov/33891379/
A Head-to-Head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-Naïve Patients With Active Psoriatic Arthritis: 24-Week Results of a Randomised, Open-Label, Blinded-Assessor Trial https://pubmed.ncbi.nlm.nih.gov/31563894/
GRAPPA Treatment Recommendations: 2021 Update https://pubmed.ncbi.nlm.nih.gov/35293339/
Deucravacitinib Prescribing Information https://packageinserts.bms.com/pi/pi_sotyktu.pdf
Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Psoriatic Arthritis: 52-Week Results From a Randomized Phase 2 Trial https://acrabstracts.org/abstract/safety-and-efficacy-of-deucravacitinib-an-oral-selective-tyrosine-kinase-2-inhibitor-in-patients-with-psoriatic-arthritis-52-week-results-from-a-randomized-phase-2-trial/
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis From the Phase 2 PAISLEY Study https://acrabstracts.org/abstract/deucravacitinib-reduces-interferons-b-cell-pathways-and-serological-biomarkers-of-systemic-lupus-disease-activity-pharmacodynamic-analysis-from-the-phase-2-paisley-study/
Nanobody: A Promising Toolkit for Molecular Imaging and Disease Therapy https://pubmed.ncbi.nlm.nih.gov/33464410/

Join Drs Stanley Cohen and Jonathan Kay as they discuss biosimilars in PsA, which will hit the US market this summer. They cover everything from working with your pharmacy to counseling patients.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984272). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview
Biosimilars for the Treatment of Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/31625769/
Biosimilars and the Extrapolation of Indications for Inflammatory Conditions https://pubmed.ncbi.nlm.nih.gov/28255229/
Adalimumab (Rx) https://reference.medscape.com/drug/amjevita-humira-adalimumab-343187
Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in Patients With Mild to Severe Psoriasis https://pubmed.ncbi.nlm.nih.gov/22229951/
Infliximab (Rx) https://reference.medscape.com/drug/remicade-inflectra-infliximab-343202
Rituximab (Rx) https://reference.medscape.com/drug/rituxan-truxima-rituximab-342243
Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site https://pubmed.ncbi.nlm.nih.gov/31587143/
Biosimilars to Bring a Bumper Crop of Adalimumab Options https://www.centerforbiosimilars.com/view/part-1-biosimilars-to-bring-a-bumper-crop-of-adalimumab-options
The Difference Between an Interchangeable Biosimilar and One That Isn't https://www.centerforbiosimilars.com/view/the-difference-between-an-interchangeable-biosimilar-and-one-that-isn-t
The Non-Medical Switching of Prescription Medications https://pubmed.ncbi.nlm.nih.gov/31081414/
Implementation of the Biologics Price Competition and Innovation Act of 2009 https://www.fda.gov/drugs/guidance-compliance-regulatory-information/implementation-biologics-price-competition-and-innovation-act-2009
Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer https://pubmed.ncbi.nlm.nih.gov/36009592/
Certolizumab pegol (Rx) https://reference.medscape.com/drug/cimzia-certolizumab-pegol-343185

Join Drs Stanley Cohen and Joseph Merola as they discuss their real-world experience running combined rheum-derm clinics for psoriatic arthritis. Listen in to hear what they consider the key to success in private practice clinics.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984273). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview
Definition of Treatment Targets in Rheumatoid Arthritis: Is It Time for Reappraisal? https://pubmed.ncbi.nlm.nih.gov/34074683/
PPACMAN https://www.ppacman.org/
Management of Psoriasis and Psoriatic Arthritis in a Combined Dermatology and Rheumatology Clinic https://pubmed.ncbi.nlm.nih.gov/21904925/
Does Biologic Therapy Impact the Development of PsA Among Patients With Psoriasis? https://pubmed.ncbi.nlm.nih.gov/34615637/
Ankylosing Spondylitis and Undifferentiated Spondyloarthropathy https://emedicine.medscape.com/article/332945-overview
Seronegative Spondyloarthropathy https://www.ncbi.nlm.nih.gov/books/NBK459356/
Utilization of the Psoriasis Epidemiology Screening Tool (PEST): A Risk Stratification Strategy for Early Referral of Psoriatic Arthritis Patients to Minimize Irreversible Erosive Joint Damage https://pubmed.ncbi.nlm.nih.gov/36214337/
Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis https://pubmed.ncbi.nlm.nih.gov/33262305/
Tumor Necrosis Factor Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK482425/
Subacute Cutaneous Lupus Erythematosus (SCLE) https://emedicine.medscape.com/article/1065657-overview
James Neil Gilliam, MD-The Career Arc of a Patient-oriented Translational Clinical Investigation Changemaker in Rheumatologic Skin Disease https://pubmed.ncbi.nlm.nih.gov/30023380/